Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimer's Disease

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|16|25|2790-2798

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.16, Iss.25, 2010-08, pp. : 2790-2798

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lessons Learnt from Glycogen Synthase Kinase 3 Inhibitors Development for Alzheimer's Disease

By  

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 15, 2013-08 ,pp. : 1808-1819

Bentham Science Publishers

Access to resources Recommend Favorite

New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease

By Medina Miguel   Avila Jesús  

Expert Opinion on Therapeutic Targets, Vol. 18, Iss. 1, 2014-01 ,pp. : 69-77

Informa Healthcare

Access to resources Recommend Favorite

Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimer's Disease

By  

Current Drug Targets, Vol. 7, Iss. 11, 2006-11 ,pp. : 1389-1397

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes

By MacAulay Katrina   Woodgett James R  

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 10, 2008-10 ,pp. : 1265-1274

Informa Healthcare

Access to resources Recommend Favorite

Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions

By  

Current Drug Targets, Vol. 7, Iss. 11, 2006-11 ,pp. : 1421-1434

Bentham Science Publishers

Access to resources Recommend Favorite